Henry Ford Health

Henry Ford Health Scholarly Commons
Cardiology Articles

Cardiology/Cardiovascular Research

1-13-2022

Exploring Physician Perceptions of the 2018 United States Heart
Transplant Allocation System
Ersilia M. Defilippis
Mitchell A. Psotka
Prateeti Khazanie
Jennifer A. Cowger
Henry Ford Health, jcowger1@hfhs.org

Rebecca Cogswell

Follow this and additional works at: https://scholarlycommons.henryford.com/cardiology_articles

Recommended Citation
Defilippis EM, Psotka MA, Khazanie P, Cowger J, and Cogswell R. Exploring Physician Perceptions of the
2018 United States Heart Transplant Allocation System. J Card Fail 2022.

This Article is brought to you for free and open access by the Cardiology/Cardiovascular Research at Henry Ford
Health Scholarly Commons. It has been accepted for inclusion in Cardiology Articles by an authorized
administrator of Henry Ford Health Scholarly Commons.

ARTICLE IN PRESS
Journal of Cardiac Failure Vol. 00 No. 00 2021

Brief Report

Exploring Physician Perceptions of the 2018 United States
Heart Transplant Allocation System
ERSILIA M. DEFILIPPIS, MD,1 MITCHELL A. PSOTKA, MD, PhD,2 PRATEETI KHAZANIE, MD, MPH,3
JENNIFER COWGER, MD,4 AND REBECCA COGSWELL, MD5
New York, New York; Falls Church, Virginia; Aurora, Colorado; Detroit, Michigan; and Minneapolis, Minnesota

ABSTRACT
Background: After the implementation of the 2018 US heart transplant allocation system, the
experience and perceptions of heart transplant clinicians have not been well-cataloged.
Methods and Results: This web-based survey of both heart failure cardiologists and surgeons
examined physician perspectives about the policy changes and whether the system is meeting
its intended goals. The majority of participants (94%, n = 113) responded that the 2018 heart
allocation system requires modiﬁcation. Eighty-four percent reported using more temporary
mechanical circulatory support to achieve higher status and 86% were concerned about the
change in physician behavior and practices under the new system.
Conclusions: Suggestions for possible improvement included higher status for patients on durable left ventricular assist device support, changes to criteria for status 2, modiﬁcation of status
exceptions, and advocacy for a heart allocation score. (J Cardiac Fail 2021;00:1 5)
Key Words: Heart transplantation, organ allocation, mechanical circulatory support.

expense of substantial increases in the use of temporary mechanical circulatory support (MCS).3,4 Additionally, because patients supported by left
ventricular assist devices (LVAD) do not reach the
highest status tiers without life-threatening complications, the use of durable LVADs as a bridge to
transplantation has decreased substantially.5 The
novel coronavirus 2019 pandemic has impacted the
ability of physicians to engage in discourse about
the new allocation system. At present, the opinions
of HT clinicians have not been well-described,
including the extent to which the system change has
met its intended goals. The purpose of this survey
was to study HT cardiologists’ and surgeons’ opinions regarding the current HT allocation system.

The US advanced heart failure and transplant
community has witnessed a dramatic change in practice since the new heart transplant (HT) organ allocation system went into effect on October 18, 2018.
The primary goal was to better stratify patients by
medical urgency and lower waitlist mortality in an
effort to distribute organs to the sickest patients.1,2
After its implementation, wait times have shortened
for patients at the highest statuses but at the
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Methods
The University of Minnesota Institutional Review
Board reviewed and approved this study. We conducted a conﬁdential, anonymous, voluntary, crosssectional, electronic, web-based survey of HT cardiologists and surgeons between September 5 and 17,
2021. The survey was developed after a review of
1
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Table 1. Survey Questions with Multiple Choice Responses
Survey Questions

Responses

I am a . . .

Heart failure surgeon
16 (13.3%)
<1
12 (10%)
Strongly agree
35 (29.2%)

Heart failure cardiologist
104 (86.7%)
1 3
15 (12.5%)
Agree
48 (40%)

3 5
18 (15%)
Somewhat agree
30 (25%)

5 10
36 (30%)
Neither
4 (3.3%)

>10
39 (32.5%)
Somewhat disagree
1 (0.8%)

Disagree
2 (1.8%)

Strongly disagree
0 (0%)

Strongly agree
22 (18.3%)

Agree
40 (33.3%)

Somewhat agree
23 (19.2%)

Neither
12 (10%)

Somewhat disagree
13 (10.8%)

Disagree
7 (5.8%)

Strongly disagree
3 (2.5%)

Strongly agree
40 (33.3%)

Agree
45 (37.5%)

Somewhat agree
16 (13.3%)

Neither
5 (4.2%)

Somewhat disagree
4 (3.3%)

Disagree
8 (6.7%)

Strongly disagree
2 (1.7%)

Strongly agree
40 (33.3%)

Agree
45 (37.5%)

Somewhat agree
16 (13.3%)

Neither
11 (9.2%)

Somewhat disagree
6 (5.0%)

Disagree
1 (0.8%)

Strongly disagree
1 (0.8%)

Strongly agree
37 (30.8%)

Agree
42 (35%)

Somewhat agree
24 (20%)

Neither
9 (7.5%)

Somewhat disagree
6 (5%)

Disagree
2 (1.7%)

Strongly disagree
0 (0%)

0
41 (34.2%)

10%
69 (57.5%)

20%
5 (4.2%)

30%
2 (1.7%)

40%
0 (0%)

50%
3 (2.5%)

Strongly agree
25 (20.8%)

Agree
29 (24.2%)

Somewhat agree
26 (21.7%)

Neither
17 (14.2%)

Somewhat disagree
11 (9.2%)

Disagree
10 (8.3%)

Strongly disagree
2 (1.7%)

Strongly agree
5 (4.2%)

Agree
17 (14.2%)

Somewhat agree
0 (0%)

Neither
61 (50.8%)

Somewhat disagree
10 (8.3%)

Disagree
18 (15%)

Strongly disagree
9 (7.5%)

Strongly agree
15 (12.5%)

Agree
35 (29.2%)

Somewhat agree
23 (19.2%)

Neither
34 (28.3%)

Somewhat disagree
6 (5%)

Disagree
6 (5%)

Strongly disagree
1 (0.8%)

How many years have you
been in practice?
I believe the allocation system
for heart
transplant instituted in
2018 (new system) requires
modiﬁcation.
I believe the new allocation
system has resulted in harm
for my patients through the
overuse of temporary
mechanical circulatory
support.
My team is utilizing more temporary support than before
the allocation system
change to achieve a higher
allocation status.
If there was a
more reliable pathway for
LVAD patients to receive a
transplant, I would be more
willing to place an LVAD
as a bridge therapy.
I am concerned about the pattern of change in physician
behavior and practices to
achieve transplant under
the new allocation system.
What percent increase in mortality is acceptable to you
(compared to the prior era)
in order to allow a pathway
for the sickest patients to
achieve a heart transplant
more quickly?
I believe the new allocation
system has stunted innovation and investment in
durable mechanical circulatory support
I believe the new allocation
system has reduced disparities (racial, gender) in heart
transplantation.
I believe the COVID-19 pandemic has negatively
impacted the HF community's ability to self monitor
during this early phase of
the new allocation system
How would you modify the
current allocation system?

the published literature and subsequent semistructured focused discussions regarding item generation
and reduction by HT clinicians, then pilot tested at
the authors’ institutions. Twitter was used to recruit
survey participants. The ﬁnal number of providers
who had access to the survey for completion is not
known. Participants accessed the survey using a web
link and software to prohibit respondents from ﬁlling out multiple surveys from the same device. No
login information was required to access the survey.
Participants were able to forward the survey

Free text response

invitation. The survey contained 2 demographic
questions (surgeon or cardiologist, years of practice),
9 statements about the new allocation system (7point Likert scale from strongly agree through
strongly disagree), and 1 free text question. No
questions were mandatory. The complete 12-question survey is displayed in Table 1. Free-text
responses were categorized thematically and summarized manually by E.M.D and R.C. Preliminary
results were presented at the 2021 Heart Failure
Society of American Annual Scientiﬁc Meeting.
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Table 2. Suggestions to Improve the Current Allocation System (n = 64)
Theme*

n (%)

Sample Comments

Improve pathway to
transplant for LVAD
patients

28 (44)

“Allow VAD patients without complications to be permanent status 3
equivalent to inotropes plus PA line.”
“Patients with durable devices should not be penalized for ‘clinical stability,’ these are the best transplant candidates.”
“Not making LVAD patients have a life-threatening complication before
they can get a transplant.”
“In recognition of the cumulative morbidity and mortality of durable VAD
support, perhaps being status 4 longer than a certain period (say 3 years)
would then qualify a patient to move to status 3 (or sooner for earlier
generation devices like HM2 and HVAD).”
“Allow increased ﬂexibility/discretionary time for durable LVAD patients,
particularly those with non-life-threatening but QOL-limiting complications of MCS.”
“Give higher allocation status to durable LVADs, particularly those
implanted prior to the allocation change.”

Modify status 2

18 (28)

“Make criteria for mechanical support stricter to require failure of
inotropes.”
“Take away award for placement of temporary MCS and award patients
who demonstrate the need. I do believe the new system awards placement of MCS when perhaps patient could similarly be supported by dual
inotropes.”
“Restrict temporary MCS to sick patients with a one-week window and bailout to VADs (combine status 1-2 for ECMO and Impella, remove IABP
from devices allowed for status 2)”
“Create further subdivision in status 2. Remove IABP as the major criteria
for status 2.”
“IABP should be a status 3 and Impella > 4L/min a status 2.”
“IABP needs to be policed better. The number of IABPs being placed to elevate status on patients on low-dose inotropes is ridiculous.”
“More emphasis on clinical status of the patient, rather than the treatment
used.”

Allocation Score

10 (16)

“LVAD time modeled and points for Black race.”
“Continuous score (ie, heartscore) modeled on expected gain in QALYs
with versus without transplant with stratiﬁed results based on whether
LVAD candidate.”
“Blood group adjustment to reduce harm of Group O.”
“Allow prioritization of sensitized patients (mostly women).”
“Make it fair. . .sick patients with inﬁltrative cardiomyopathies, HOCM do
not have a way out to higher listing than others.”
“There needs to be status priority adjustment for highly sensitized patients
as well as for those who do not have LVAD option (severe RV failure, congenital, etc) as the number of transplants done at status 4 6 drops.”

Regulate Exceptions

6 (9)

“Largest problem with current system is actually the utilization of exception requests and the almost universal acceptance of these requests.”
“Increasing need for exception letters demonstrates the gaps in current system. Would suggest study of exceptions sought and reasons for apply for
exception (physiology, ie, are we ignoring a speciﬁc phenotype like ARVC
versus SBP missed cutoff by 2 points).”
“Need to have more restrictions on exemptions”
“Reduce requirements for exceptions. . .that have become the norm.”
“Stricter regional review board oversight on status exemption requests
may also be necessarily to limit ‘creep’ of the statuses into patients for
whom they were not designed.”

Other

6 (9)

“I would not allow for transplant off ECMO. I would place a much more
stringent limitation on duration of temporary mechanical support (eg, 2
weeks).”
“Despite the hope that the new system would decrease geographic inequities, I feel that our experience [. . .] equates to a worsening of regional
disparities.”
“Change distance allocation to allow for a system that incorporates acuity
of patient and distance of donor together”.

*Respondents could be counted more than once if they suggested multiple themes. ARVC, arrhythmogenic right ventricular cardiomyopathy; ECMO, extracorporeal membrane oxygenation; HOCM, hypertrophic cardiomyopathy; IABP, intra-aortic balloon pump; LVAD,
left ventricular assist device; MCS, mechanical circulatory support; PA, pulmonary artery; RV, right verntricular; QOL, Quality of life; SBP,
systolic blood pressure; VAD, ventricular assist device;
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Fig. 1. Physician opinions about the 2018 heart transplant allocation system. Major concerns regarding the 2018 allocation
system are depicted and potential solutions suggested. AIBP, intra-aortic balloon pump; LVAD, left ventricular assist
device.

Results
There were 120 respondents, the majority of whom
(87%, n = 104) were HT cardiologists. Thirty-two percent of the survey participants had been in practice
for more than 10 years, 30.0% in practice for
5 10 years, and the remainder had been in practice
for fewer than 5 years. The summary data for each
response are displayed in Table 1. The majority of participants (94%, n = 113) responded that the new heart
allocation system requires modiﬁcation and 84%
(n = 101) reported an increase in their institution’s use
of temporary MCS. Eighty-ﬁve percent (n = 103) were
concerned about the pattern in physician behaviors
and practices to achieve transplant under the new
allocation system. Seventy percent (n = 85) believe the
new allocation system could harm patients through
the overuse of temporary MCS.
Eighty-four percent of respondents (n = 101)
agreed that they would be more willing to place an
LVAD as bridge therapy if there was a more reliable
pathway for LVAD patients to be transplanted.
When asked whether the new allocation system has
decreased racial and gender disparities within HT,
the majority neither agreed nor disagreed (51%,
n = 61). When asked what percent increase in mortality is acceptable (compared with the prior allocation era) to allow a pathway for the sickest patients
to achieve HT quicker, the majority of respondents

(92%, n = 110) chose the lowest risk categories
(0% 10 %).
Free-text substantive suggestions for the allocation system were completed by 66 participants
(55%). Among the free-text answers, 1 participant
stated that more time was needed to assess the current allocation system impact and another felt that
temporary MCS was justiﬁed based on poor performance of LVADs. Suggestions for modiﬁcation
(n = 64) are outlined and sample comments are provided (Table 2). These included advocating for an
easier pathway to transplant for LVAD patients
(44%, n = 28), modifying the current status 2 (28%,
n = 18), and using a heart allocation score (16%,
n = 10). Regulating exceptions more closely was suggested by 9% (n = 6) of respondents. With respect to
a potential allocation score, accounting for LVAD
time, race, sensitization, and blood group O were all
suggested.
Conclusions
This sample of advanced heart failure cardiologists and surgeons believe revisions are needed to
the 2018 HT allocation system. The increasing use of
exceptions, temporary MCS, and highest tier statuses to facilitate HT may be a cyclical problem. As
more programs escalate by exception or temporary
MCS use to higher listing statuses, higher status
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listings are required for HT. Physicians use more temporary MCS under the current system and they are
concerned this increases the risk for patient harm.
The lack of a more rapid pathway to transplant for
patients on LVAD support may also contribute to
riskier MCS use, as physicians balance the safety of
longer temporary MCS support with avoidance of a
long-term LVAD. In addition, disparities may be perpetuated through differences in the use of temporary and durable MCS between centers and patient
populations, particularly disenfranchised patients. It
remains unclear how the 2018 allocation system
may impact racial and gender disparities and further
dedicated analyses are required to assess these
issues. Such analyses may inform the eventual construction of an equitable heart allocation score.
These survey data can help to inform ongoing iterations of the HT allocation system. Although plans
exist to begin modeling a heart allocation score in
2023, building this model, allowing for public comment, and implementing it will take time. We hope
to foster a dialogue within the community about
whether modiﬁcations within the existing system
could be accomplished more quickly. Examples
might include allowing higher listing status for
patients with LVADs based on complications or time
on LVAD support, or modifying status 2 to exclude
IABP use (Fig. 1). Although an argument could be
made to allow more time to determine whether the
current trends will be sustained, the physician community sampled felt that modiﬁcations are needed
to improve the equitable distribution of organs.
This study has limitations. Because participants
were recruited through social medial platforms
and snowball sampling, there was a selection
bias. Such respondents may have been motivated
to complete the survey if they disapproved of the
current policy. Second, the sample size is small.
Third, we could not calculate a response rate for
this survey owing to snowball sampling and the
lack of a denominator of eligible participants.
Fourth, demographic information with respect to
the physicians including age, sex, race, ethnicity,
program size, and geography were not collected.

However, despite these limitations, this survey
helps in the ongoing re-evaluation of the policy
change within the transplant community to
develop durable improvements to the current
allocation system for the beneﬁt of all patients
awaiting HT.
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